Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation : a Portuguese multicentre study

Glioblastoma (GBM) is the most common and aggressive primary brain tumor. The identification of novel molecular prognostic markers of GBM has recently been an area of great interest in neuro-oncology. The methylation status of the MGMT gene promoter is currently a promising molecular prognostic mark...

ver descrição completa

Detalhes bibliográficos
Autor principal: Costa, Bruno Marques (author)
Outros Autores: Caeiro, Cláudia (author), Guimarães, Inês (author), Martinho, Olga (author), Jaraquemada, Teresa (author), Augusto, Isabel (author), Castro, Lígia (author), Osório, Lígia (author), Linhares, Paulo (author), Honavar, Mrinalini (author), Resende, Mário (author), Braga, Fátima (author), Silva, Ana (author), Pardal, Fernando (author), Amorim, Júlia (author), Nabiço, Rui (author), Almeida, Rui (author), Alegria, Carlos (author), Pires, Manuel (author), Pinheiro, Célia (author), Carvalho, Ernesto (author), Lopes, José M. (author), Costa, Paulo (author), Damasceno, Margarida (author), Reis, R. M. (author)
Formato: article
Idioma:eng
Publicado em: 2010
Assuntos:
Glioblastoma
Prognosis
MGMT methylation
Temozolomide
Chemoradiation
Science & Technology
Texto completo:http://hdl.handle.net/1822/29360
País:Portugal
Oai:oai:repositorium.sdum.uminho.pt:1822/29360

Texto Completo

http://hdl.handle.net/1822/29360

Registros relacionados